INTERLEUKIN-17A IS A NEW TARGET OF ANTICYTOKINE THERAPY FOR ANKYLOSING SPONDYLITIS
https://doi.org/10.14412/1995-4484-2016-1S-60-66
Abstract
Therapy for ankylosing spondylitis (AS) is a challenge for a physician, primarily because of a small number of therapeutic alternatives. Interleukin-17 (IL17), a novel promising therapeutic target, has been recently disclosed. The first representative of the new group of drugs – anti-IL17A monoclonal antibodies (secukinumab) has emerged, which allows expanding therapeutic opportunities for this disease. Trials have shown that secukinumab is effective in treating AS, has low immunogenicity and its safety profile does not virtually differ from that of placebo.
About the Author
Sh. F. Erdes
V.A. Nasonova Research Institute of Rheumatology, Moscow
Russian Federation
Erdes Shandor
Russian Federation
Erdes Shandor
References
1. McGonagle D. A proposed classification of the immunological diseases. PLOS Med. 2006;3:e297. doi: 10.1371/journal.pmed.0030297
2. Limon-Camacho L, Vargas-Rojas MI, Vazquez-Mellado J, et al. In vivo peripheral blood proinflammatory T cells in patients with ankylosing spondylitis. J Rheumatol. 2012;39:830-5. doi: 10.3899/jrheum.110862
3. Mattey DL, Packham JC, Nixon NB, et al. Association of cytokine and matrix metalloproteinase profiles with disease activity and function in ankylosing spondylitis. Arthritis Res Ther. 2012;14:R127. doi: 10.1186/ar3857
4. Mei Y, Pan F, Gao J, et al. Increased serum IL-17 and IL-23 in the patient with ankylosig spondylitis. Clin Rheumatol. 2011;30:269-73. doi: 10.1007/s10067-010-1647-4
5. Liu W, Wu YH, Zhang L, et al. Elevated serum levels of IL-6 and IL-17 may associate with the development of ankylosing spondylitis. Int J Clin Exp Med. 2015 Oct 15;8(10):17362-76.
6. Насонов ЕЛ, Денисов ЛН, Станислав МЛ. Интерлейкин 17 – новая мишень для антицитокиновой терапии иммуновоспалительных ревматических заболеваний. Научно-практическая ревматология. 2013;51(5):545-52 [Nasonov EL, Denisov LN, Stanislav ML. Interleukin-17 is a new target for anti-cytokine therapy of immune inflammatory rheumatic diseases. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2013;51(5):545-52 (In Russ.)]. doi: 10.14412/1995-4484-2013-1547
7. Chen WS, Chang YS, Lin KC, et al. Association of serum interleukin-17 and interleukin-23 levels with disease activity in Chinese patients with ankylosing spondylitis. J Chin Med Assoc. 2012;75:303-8. doi: 10.1016/j.jcma.2012.05.006
8. Davis JC Jr, van der Heijde D, Braun J, et al. Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial. Arthritis Rheum. 2003;48:3230-6. doi: 10.1002/art.11325
9. Van der Heijde D, Dijkmans B, Geusens P, et al. Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT). Arthritis Rheum. 2005;52:582-91. doi: 10.1002/art.20852
10. Van der Heijde D, Schiff MH, Sieper J, et al. Adalimumab effectiveness for the treatment of ankylosing spondylitis is maintained for up to 2 years: long-term results from the ATLAS trial. Ann Rheum Dis. 2009;68:922-9. doi: 10.1136/ard.2007.087270
11. Baeten D, Baraliakos X, Braun J, et al. Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial. Lancet. 2013;382:1705-13. doi: 10.1016/S0140-6736(13)61134-4
12. Baraliakos X, Borah B, Braun J, et al. Long-term effects of secukinumab on MRI findings in relation to clinical efficacy in subjects with active ankylosing spondylitis: an observational study. Ann Rheum Dis. 2016;75:408-12. doi: 10.1136/annrheumdis-2015-207544
13. Baeten D, Sieper J, Braun J, et al. Secukinumab, an interleukin-17A inhibitor, in ankylosing spondylitis. N Engl J Med. 2015;373:2534-48. doi: 10.1056/NEJMoa1505066
14. Braun J, van den Berg R, Baraliakos X, et al. 2010 Update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis. 2011;70:896-904. doi: 10.1136/ard.2011.151027
15. Inman RD, Davis JC Jr, van der Heijde D, et al. Efficacy and safety of golimumab in patients with ankylosing spondylitis: results of a randomized, double-blind, placebo-controlled, phase III trial. Arthritis Rheum. 2008;58:3402-12. doi: 10.1002/art.23969
16. Van der Heijde D, Kivitz A, Schiff MH, et al. Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2006;54:2136-46. doi: 10.1002/art.21913
17. Landewe R, Braun J, Deodhar A, et al. Efficacy of certolizumab pegol on signs and symptoms of axial spondyloarthritis including ankylosing spondylitis: 24-week results of a double-blind randomized placebo-controlled Phase 3 study. Ann Rheum Dis. 2014;73:39-47. doi: 10.1136/annrheumdis-2013-204231
18. Baeten D, Blanco R, Geusens P, et al. Secukinumab provides sustained improvements in the signs and symptoms of active ankylosing spondylitis in anti-TNF-naive patients and those previously exposed to anti-TNF therapy: 52-week results from two randomized, double-blind, placebo-controlled phase 3 trials [abstract]. Arthritis Rheum. 2015;67(Suppl. 10).
19. Langley RG, Elewski BE, Lebwohl M, et al. Secukinumab in plaque psoriasis – results of two phase 3 trials. N Engl J Med. 2014;371:326-38. doi: 10.1056/NEJMoa1314258.
Review
For citations:
Erdes Sh.F. INTERLEUKIN-17A IS A NEW TARGET OF ANTICYTOKINE THERAPY FOR ANKYLOSING SPONDYLITIS. Rheumatology Science and Practice. 2016;54(1S):60-66. (In Russ.) https://doi.org/10.14412/1995-4484-2016-1S-60-66
Views:
1101
Email this article 